Equities analysts expect Sangamo Therapeutics Inc (NASDAQ:SGMO) to report sales of $14.01 million for the current quarter, Zacks reports. Four analysts have made estimates for Sangamo Therapeutics’ earnings, with estimates ranging from $8.10 million to $18.10 million. Sangamo Therapeutics posted sales of $23.56 million during the same quarter last year, which suggests a negative year-over-year growth rate of 40.5%. The firm is scheduled to issue its next quarterly earnings results on Thursday, November 14th.

On average, analysts expect that Sangamo Therapeutics will report full-year sales of $55.54 million for the current fiscal year, with estimates ranging from $46.00 million to $62.30 million. For the next fiscal year, analysts forecast that the company will post sales of $105.66 million, with estimates ranging from $55.10 million to $240.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.09. The business had revenue of $17.55 million for the quarter, compared to analysts’ expectations of $13.58 million. Sangamo Therapeutics had a negative net margin of 136.73% and a negative return on equity of 27.32%. The business’s revenue was down 18.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.17) earnings per share.

A number of analysts have recently issued reports on SGMO shares. HC Wainwright started coverage on shares of Sangamo Therapeutics in a research note on Monday, August 26th. They set a “buy” rating and a $16.00 target price for the company. Zacks Investment Research raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 17th. BidaskClub lowered shares of Sangamo Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, October 3rd. Wedbush set a $11.00 target price on shares of Sangamo Therapeutics and gave the company a “hold” rating in a research note on Monday, July 8th. Finally, ValuEngine raised shares of Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $14.00.

Shares of SGMO traded down $0.32 during trading hours on Thursday, reaching $8.32. 842,600 shares of the company traded hands, compared to its average volume of 1,404,325. The firm has a market cap of $998.28 million, a price-to-earnings ratio of -11.88 and a beta of 2.81. Sangamo Therapeutics has a 12-month low of $6.26 and a 12-month high of $14.58. The stock’s fifty day moving average price is $9.74 and its 200 day moving average price is $10.67.

Large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new stake in Sangamo Therapeutics in the second quarter worth about $229,000. Wells Fargo & Company MN lifted its position in shares of Sangamo Therapeutics by 25.1% during the second quarter. Wells Fargo & Company MN now owns 821,420 shares of the biopharmaceutical company’s stock valued at $8,847,000 after buying an additional 164,784 shares during the last quarter. Artal Group S.A. lifted its position in shares of Sangamo Therapeutics by 1.3% during the second quarter. Artal Group S.A. now owns 405,000 shares of the biopharmaceutical company’s stock valued at $4,362,000 after buying an additional 5,000 shares during the last quarter. Virtus ETF Advisers LLC purchased a new stake in shares of Sangamo Therapeutics during the second quarter valued at about $308,000. Finally, Sector Gamma AS lifted its position in shares of Sangamo Therapeutics by 5.4% during the second quarter. Sector Gamma AS now owns 251,698 shares of the biopharmaceutical company’s stock valued at $2,711,000 after buying an additional 12,841 shares during the last quarter. 69.02% of the stock is owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

Featured Article: What are the Different Types of Leveraged Buyouts?

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.